NDAORALTABLET
Approved
Aug 2017
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
DUZALLO (allopurinol; lesinurad) by Ironwood Pharmaceuticals is allopurinol acts on purine catabolism, without disrupting the biosynthesis of purines. Approved for leukemia, lymphoma. First approved in 2017.
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DUZALLO is a fixed-dose oral combination of allopurinol (xanthine oxidase inhibitor) and lesinurad (uricosuric agent) approved in 2017 for hyperuricemia in patients with leukemia and lymphoma. It reduces uric acid production by inhibiting the enzyme responsible for converting hypoxanthine and xanthine to uric acid, while lesinurad enhances renal clearance. This dual mechanism provides complementary uric acid-lowering effects in cancer patients at risk of tumor lysis syndrome.
Peak5.3 years to LOE
Product is at peak lifecycle stage with 5.4 years of patent protection remaining; commercial teams are likely stable but face approaching LOE planning urgency.
Mechanism of Action
Allopurinol acts on purine catabolism, without disrupting the biosynthesis of purines. It reduces the production of uric acid by inhibiting the biochemical reactions immediately preceding its formation. Allopurinol is a structural analogue of the natural purine base, hypoxanthine. It is an…
Worked on DUZALLO at Ironwood Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.